Sensus Healthcare Inc (SRTS)

$6.09

+0.24

(+4.1%)▲

Market is closed - opens 7 PM, 16 Sep 2024

Performance

  • $5.91
    $6.24
    $6.09
    downward going graph

    2.96%

    Downside

    Day's Volatility :5.29%

    Upside

    2.4%

    downward going graph
  • $1.79
    $7.18
    $6.09
    downward going graph

    70.61%

    Downside

    52 Weeks Volatility :75.07%

    Upside

    15.18%

    downward going graph

Returns

PeriodSensus Healthcare IncIndex (Russel 2000)
3 Months
8.74%
0.0%
6 Months
50.39%
0.0%
1 Year
116.67%
0.0%
3 Years
64.79%
-21.1%

Highlights

Market Capitalization
96.4M
Book Value
$1.57
Earnings Per Share (EPS)
0.41
PE Ratio
14.34
PEG Ratio
0.0
Wall Street Target Price
10.67
Profit Margin
18.27%
Operating Margin TTM
40.84%
Return On Assets TTM
9.7%
Return On Equity TTM
13.44%
Revenue TTM
36.4M
Revenue Per Share TTM
2.23
Quarterly Revenue Growth YOY
155.7%
Gross Profit TTM
29.6M
EBITDA
8.8M
Diluted Eps TTM
0.41
Quarterly Earnings Growth YOY
4.33
EPS Estimate Current Year
0.37
EPS Estimate Next Year
0.57
EPS Estimate Current Quarter
0.02
EPS Estimate Next Quarter
-0.02

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Sensus Healthcare Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
9
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 75.21%

Current $6.09
Target $10.67

Company Financials

FY18Y/Y Change
Revenue
26.4M
↑ 28.36%
Net Income
-2.0M
↓ 45.49%
Net Profit Margin
-7.65%
↑ 10.37%
FY19Y/Y Change
Revenue
27.3M
↑ 3.16%
Net Income
-1.2M
↓ 42.94%
Net Profit Margin
-4.23%
↑ 3.42%
FY20Y/Y Change
Revenue
9.6M
↓ 64.87%
Net Income
-4.7M
↑ 308.5%
Net Profit Margin
-49.24%
↓ 45.01%
FY21Y/Y Change
Revenue
27.0M
↑ 182.37%
Net Income
4.1M
↓ 187.35%
Net Profit Margin
15.23%
↑ 64.47%
FY22Y/Y Change
Revenue
44.5M
↑ 64.68%
Net Income
24.2M
↑ 488.59%
Net Profit Margin
54.44%
↑ 39.21%
FY23Y/Y Change
Revenue
24.4M
↓ 45.2%
Net Income
485.0K
↓ 98.0%
Net Profit Margin
1.99%
↓ 52.45%
Q1 FY23Q/Q Change
Revenue
3.4M
↓ 73.95%
Net Income
-1.9M
↓ 166.95%
Net Profit Margin
-55.48%
↓ 77.07%
Q2 FY23Q/Q Change
Revenue
4.5M
↑ 32.6%
Net Income
-380.0K
↓ 79.94%
Net Profit Margin
-8.39%
↑ 47.09%
Q3 FY23Q/Q Change
Revenue
3.9M
↓ 13.89%
Net Income
-1.5M
↑ 281.84%
Net Profit Margin
-37.22%
↓ 28.83%
Q4 FY23Q/Q Change
Revenue
12.6M
↑ 222.37%
Net Income
4.2M
↓ 390.14%
Net Profit Margin
33.5%
↑ 70.72%
Q1 FY24Q/Q Change
Revenue
10.7M
↓ 15.14%
Net Income
2.3M
↓ 45.99%
Net Profit Margin
21.33%
↓ 12.17%
Q2 FY24Q/Q Change
Revenue
9.2M
↓ 13.35%
Net Income
1.6M
↓ 29.11%
Net Profit Margin
17.45%
↓ 3.88%
FY18Y/Y Change
Total Assets
33.3M
↑ 76.54%
Total Liabilities
6.8M
↓ 5.08%
FY19Y/Y Change
Total Assets
36.9M
↑ 11.05%
Total Liabilities
8.9M
↑ 31.39%
FY20Y/Y Change
Total Assets
28.0M
↓ 24.14%
Total Liabilities
6.5M
↓ 27.0%
FY21Y/Y Change
Total Assets
32.2M
↑ 15.1%
Total Liabilities
6.2M
↓ 4.44%
FY22Y/Y Change
Total Assets
56.7M
↑ 75.98%
Total Liabilities
8.7M
↑ 39.21%
FY23Y/Y Change
Total Assets
53.7M
↓ 5.3%
Total Liabilities
4.9M
↓ 43.63%
Q1 FY23Q/Q Change
Total Assets
53.4M
↓ 5.88%
Total Liabilities
7.1M
↓ 18.37%
Q2 FY23Q/Q Change
Total Assets
52.0M
↓ 2.59%
Total Liabilities
6.0M
↓ 15.08%
Q3 FY23Q/Q Change
Total Assets
50.5M
↓ 2.83%
Total Liabilities
6.0M
↓ 0.8%
Q4 FY23Q/Q Change
Total Assets
53.7M
↑ 6.29%
Total Liabilities
4.9M
↓ 18.02%
Q1 FY24Q/Q Change
Total Assets
57.3M
↑ 6.6%
Total Liabilities
6.1M
↑ 24.18%
Q2 FY24Q/Q Change
Total Assets
58.2M
↑ 1.55%
Total Liabilities
5.3M
↓ 13.25%
FY18Y/Y Change
Operating Cash Flow
-8.6M
↑ 180.17%
Investing Cash Flow
-2.6M
↓ 142.8%
Financing Cash Flow
13.6M
↑ 606.5%
FY19Y/Y Change
Operating Cash Flow
-2.1M
↓ 75.4%
Investing Cash Flow
-4.9M
↑ 85.36%
Financing Cash Flow
2.6M
↓ 80.74%
FY20Y/Y Change
Operating Cash Flow
-434.2K
↓ 79.39%
Investing Cash Flow
7.0M
↓ 243.55%
Financing Cash Flow
210.0K
↓ 91.99%
FY21Y/Y Change
Operating Cash Flow
-286.0K
↓ 34.13%
Investing Cash Flow
129.0K
↓ 98.17%
Financing Cash Flow
-231.0K
↓ 210.0%
FY22Y/Y Change
Operating Cash Flow
-1.4M
↑ 393.71%
Investing Cash Flow
14.8M
↑ 11404.65%
Financing Cash Flow
-2.4M
↑ 951.08%
Q1 FY23Q/Q Change
Operating Cash Flow
149.0K
↓ 101.47%
Investing Cash Flow
-189.0K
↑ 1790.0%
Financing Cash Flow
6.0K
↓ 100.31%
Q2 FY23Q/Q Change
Operating Cash Flow
742.0K
↑ 397.99%
Investing Cash Flow
-29.0K
↓ 84.66%
Financing Cash Flow
0.0
↓ 100.0%

Technicals Summary

Sell

Neutral

Buy

Sensus Healthcare Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sensus Healthcare Inc
Sensus Healthcare Inc
-9.02%
50.39%
116.67%
64.79%
-8.16%
Stryker Corporation
Stryker Corporation
11.79%
3.05%
23.7%
35.8%
68.57%
Boston Scientific Corp.
Boston Scientific Corp.
10.42%
26.94%
57.58%
89.62%
100.5%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
2.68%
-26.69%
-6.89%
-42.92%
-6.88%
Abbott Laboratories
Abbott Laboratories
7.94%
-2.77%
13.77%
-7.73%
38.64%
Medtronic Plc
Medtronic Plc
9.4%
5.78%
10.67%
-30.79%
-17.94%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sensus Healthcare Inc
Sensus Healthcare Inc
14.34
14.34
0.0
0.37
0.13
0.1
NA
1.57
Stryker Corporation
Stryker Corporation
41.0
41.0
2.7
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
68.15
68.15
2.06
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.87
26.87
3.25
2.66
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
36.85
36.85
4.26
4.23
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.3
30.3
1.67
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sensus Healthcare Inc
Sensus Healthcare Inc
Buy
$96.4M
-8.16%
14.34
18.27%
Stryker Corporation
Stryker Corporation
Buy
$140.2B
68.57%
41.0
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$123.5B
100.5%
68.15
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$41.1B
-6.88%
26.87
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$203.3B
38.64%
36.85
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.4B
-17.94%
30.3
12.06%

Insights on Sensus Healthcare Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 12.56M → 9.23M (in $), with an average decrease of 14.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 4.21M → 1.61M (in $), with an average decrease of 37.6% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 89.6% return, outperforming this stock by 24.8%

Institutional Holdings

  • Vanguard Group Inc

    4.75%

  • Renaissance Technologies Corp

    2.39%

  • Two Sigma Investments LLC

    1.22%

  • Dimensional Fund Advisors, Inc.

    1.02%

  • Two Sigma Advisers, LLC

    1.01%

  • Geode Capital Management, LLC

    0.82%

Company Information

sensus healthcare, inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancer and keloids. sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (srt), which is a result of over a decade of dedicated research and development activities. sensus has successfully incorporated the srt therapy into its portfolio of treatment devices: srt-100™ and srt-100 vision™. srt technology effectively and safely treats oncological and non-oncological skin conditions. for more information, visit http://www.sensushealthcare.com.

Organization
Sensus Healthcare Inc
Employees
35
CEO
Mr. Joseph C. Sardano
Industry
Health Technology

Discover More

FAQs